Selank: Cognitive / Neuro research guide

Selank is a Russian anxiolytic heptapeptide derived from the immune peptide tuftsin that produces benzodiazepine-like calming effects through GABAA modulation - without sedation, amnesia, or dependence.

One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.

Peer-reviewed literature typically discusses Selank in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.

Typical study contexts

• Stress, sleep, and neuronal signalling in rodents; peptide tools for probing pathways, not treating human cognition.
• Some compounds appear in small exploratory human studies elsewhere in the literature, still distinct from DIY use.
• Peer-reviewed preclinical work sometimes describes experiments that track whether allosterically modulates GABAA receptor affinity, anxiolytic profile comparable to benzodiazepines without sedation or dependence
• Peer-reviewed preclinical work sometimes describes experiments that track whether rapidly elevates BDNF expression in hippocampal neurons for neurotrophic support
• Peer-reviewed preclinical work sometimes describes experiments that track whether modulates monoamine neurotransmitter levels, significantly alters noradrenaline, dopamine, and serotonin concentrations
• Peer-reviewed preclinical work sometimes describes experiments that track whether inhibits enkephalin-degrading enzymes to potentiate endogenous opioid peptide signaling

Cognitive-related peptides are explored for stress-response pathways, neuronal signalling, and behaviour in animal models -not as treatments for human brain conditions.

Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.

• Allosterically modulates GABAA receptor affinity, anxiolytic profile comparable to benzodiazepines without sedation or dependence
• Rapidly elevates BDNF expression in hippocampal neurons for neurotrophic support
• Modulates monoamine neurotransmitter levels, significantly alters noradrenaline, dopamine, and serotonin concentrations
• Inhibits enkephalin-degrading enzymes to potentiate endogenous opioid peptide signaling
• Regulates IL-6 expression and T-helper cell cytokine balance for immunomodulatory effects
• Demonstrated antiasthenic and psychostimulant effects beyond pure anxiolysis in clinical trials

Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.

Research dosing context: Literature typically discusses 250–500 μg intranasal; 150–300 μg subcutaneous · Once daily intranasal (0.15% solution, 2–3 drops per nostril) · Complete plasma clearance within 10 minutes post-administration. C-terminal Pro-Gly-Pro extension substantially extends biological activity duration versus native tuftsin (t½ seconds). Intranasal route preferred for non-invasive CNS delivery. Metabolized rapidly in the liver and eliminated via renal excretion. Russian clinical doses: 150–300 μg intranasally, with anxiolytic effects observed within 10–15 minutes of administration.

Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.

Other compounds researchers often read about alongside Selank.

• Semax - companion guide
• Cerebrolysin - companion guide
• TB-500 - companion guide
• BPC-157 - companion guide

Primary literature and registries for Selank, plus mainstream coverage of the peptide category. Research use only - not medical advice.

Databases & literature:

• PubMed: peer-reviewed literature on Selank
• ClinicalTrials.gov: registered studies on Selank
• Selank: Wikipedia

Peptides in the news:

• WebMD: consumer health reference
• BBC News: Health
• CNN Health: “Peptides: what to know about the wellness trend”
• Sky News: “Can peptides make America healthy again?”
• Sky News: “Inside the exploding US peptides craze” (video)
• Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”
• Sky News Australia: “Backyard peptide boom sparks alarm” (video)
• Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”